Explore the latest global research on SGLT2 inhibitors, highlighting their cardiovascular, renal, metabolic, and multi-organ protective benefits. From real-world studies to randomized trials, discover how these agents are reshaping modern cardio-renal-metabolic care in 2026.
A multi-center retrospective cohort study evaluated the association between SGLT2 inhibitor use and biliary disease risk in 1,901 adults with type 2 diabetes mellitus. Compared with sulfonylureas, SGLT2 inhibitor users had a significantly lower risk of biliary diseases after propensity score adjustment (HR 0.595; 95% CI 0.410–0.863; p = 0.020). The protective association remained significant beyond 24 months and was stronger in patients over 60 years, those without diabetic complications, and individuals with higher comorbidity burdens. Glycemic control and body weight were comparable between groups, while SGLT2 inhibitor users demonstrated higher HDL cholesterol and lower total bile acid and bilirubin levels. These findings suggest that SGLT2 inhibitors may confer protective biliary effects beyond glucose lowering, particularly with long-term use and in high-risk populations.
Read MoreA single-center retrospective cohort study assessed the effectiveness and safety of SGLT2 inhibitors in 65 kidney transplant recipients with post-transplant diabetes mellitus treated for more than three months. Over a mean treatment duration of 2.56 years, allograft function remained stable, with no significant decline in estimated glomerular filtration rate and no increase in proteinuria markers. Patients experienced significant reductions in body weight, body mass index, systolic and diastolic blood pressure, total cholesterol, LDL cholesterol, and serum uric acid. Electrolytes remained stable, and no cases of euglycemic diabetic ketoacidosis, allograft rejection, or genital infections were observed. These real-world findings indicate that SGLT2 inhibitors are associated with preserved graft function, meaningful cardiometabolic improvements, and a favorable safety profile in this high-risk population.
Read MoreA large propensity-matched study using the TriNetX database evaluated the association between SGLT2 inhibitor use and outcomes in adults with degenerative aortic stenosis. After matching 10,912 patients per group, SGLT2 inhibitor use was independently associated with significantly lower all-cause mortality, reduced need for transcatheter and surgical aortic valve replacement, and fewer cardiac arrests and cases of end-stage kidney disease. Although echocardiographic progression parameters were not available, these clinical outcome improvements suggest a potential valve-preserving effect. The findings extend the established cardiovascular and renal benefits of SGLT2 inhibitors and indicate a possible role in modifying disease trajectory in degenerative aortic stenosis. Prospective studies with standardized imaging are needed to confirm whether these agents directly influence valve hemodynamics.
Read MoreA quasi-experimental study involving 148 patients with type 2 diabetes assessed the impact of SGLT2 inhibitors on renal resistive index and urine albumin-to-creatinine ratio over three months. Participants were categorized into normoalbuminuric and microalbuminuric groups and evaluated using Doppler ultrasonography. Post-treatment analysis demonstrated significant reductions in renal resistive index and albuminuria, indicating improved renal microvascular function and hemodynamics. These findings reinforce the renal protective role of SGLT2 inhibitors in diabetic nephropathy and support their therapeutic relevance in preserving renal microcirculation. The results highlight benefits extending beyond glycemic control, suggesting that SGLT2 inhibitors may help delay progression toward end-stage renal disease.
Read MoreSGLT2 inhibitors reduce glucose reabsorption in the kidneys and lower blood sugar independent of insulin, with a low risk of hypoglycemia. Beyond glycemic control, clinical studies show significant cardiovascular and renal benefits. Large heart failure trials demonstrate reduced hospitalization for heart failure, slower progression of chronic kidney disease, and lower cardiovascular mortality, even in individuals without diabetes. Additional benefits include modest weight loss and blood pressure reduction. Proposed mechanisms include favorable changes in blood flow, cardiac function, metabolism, and inflammation. Although genital infections and rare cases of euglycemic ketoacidosis may occur, overall benefits outweigh risks with appropriate patient selection. These findings position SGLT2 inhibitors as important agents in integrated cardio-renal-metabolic care.
Read MoreThis retrospective study evaluated whether treatment sequencing between SGLT2 inhibitors and GLP-1 receptor agonists influences renal outcomes in 565 adults with type 2 diabetes. Over a median 4.3-year follow-up, patients initiating therapy with an SGLT2 inhibitor experienced a significantly slower annual decline in estimated glomerular filtration rate compared with those starting with a GLP-1 receptor agonist. The benefit was more pronounced in individuals with chronic kidney disease at baseline. Changes in albuminuria, HbA1c, and body weight were similar between groups. These findings suggest that early initiation of SGLT2 inhibitors may confer greater long-term renal protection, supporting their role as foundational therapy for preserving kidney function in type 2 diabetes.
Read MoreA multi-center retrospective cohort study evaluated the effectiveness and safety of SGLT2 inhibitors in diabetic patients aged 75 years and older. Among 2,089 matched patients with a mean age of 83.5 years, SGLT2 inhibitor use was associated with significantly lower all-cause mortality and reduced worsening of renal function over up to five years of follow-up. Cardiovascular mortality and heart failure hospitalization rates were similar between groups. Importantly, urinary tract infection rates did not increase with SGLT2 inhibitor use. Benefits were more pronounced in patients aged 75–85 years and appeared reduced in those older than 85 years. These findings support the cardio-renal benefits and safety of SGLT2 inhibitors in older adults with diabetes, with careful selection in the very elderly.
Read MoreA systematic review and meta-analysis of 15 randomized controlled trials involving 8,296 participants evaluated the efficacy and safety of empagliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease. Empagliflozin significantly reduced HbA1c levels (SMD −0.62; 95% CI −0.95 to −0.30; p = 0.0001), reflecting improved glycemic control. Significant reductions in body weight were also observed (SMD −2.32; 95% CI −3.42 to −1.21; p < 0.0001). Additionally, favorable effects were noted across cardiovascular indicators and laboratory parameters. Subgroup and meta-regression analyses provided further insight into variability across populations. This pooled analysis supports the efficacy of empagliflozin in improving glycemic control and weight while demonstrating benefits relevant to cardiovascular management in patients with T2DM and CVD.
Read MoreA nationwide Japanese real-world study evaluated 24,830 treatment-naïve adults with type 2 diabetes receiving DPP-4 inhibitors, SGLT2 inhibitors, or metformin. The study assessed whether physical activity influenced glycemic outcomes, defined as achieving HbA1c <6.5%. Among patients treated with SGLT2 inhibitors, physically active individuals had significantly higher odds of achieving glycemic control compared to sedentary individuals. A similar association was observed with DPP-4 inhibitors, while no significant association was seen with metformin. These findings highlight the effectiveness of SGLT2 inhibitors in real-world practice and support the integration of lifestyle interventions with pharmacologic therapy. The results reinforce the value of combining SGLT2 inhibitors with physical activity to optimize glycemic management in type 2 diabetes.
Read MoreA multicenter retrospective cohort study evaluated discrepancies between HbA1c and glucose management indicator (GMI) in patients receiving SGLT2 inhibitors. The study included 136 patients, with 109 in the SGLT2 inhibitor group and 27 in the control group. After adjustment using inverse probability of treatment weighting, the difference between HbA1c and GMI was significantly higher in the SGLT2 inhibitor group (b = 0.42; 95% CI 0.14–0.70; P = 0.003). These findings suggest that patients treated with SGLT2 inhibitors may have higher HbA1c values relative to their actual glycemic status as assessed by continuous glucose monitoring. The study indicates that SGLT2 inhibitors are associated with effective glycemic control that may not be fully reflected by HbA1c alone.
Read MoreA retrospective cohort study in Indonesia evaluated the effectiveness of SGLT2 inhibitors alone or in combination with GLP-1 receptor agonists over at least 12 months in patients with type 2 diabetes. Among 111 patients, significant intergroup differences were observed in systolic and diastolic blood pressure. The combination group demonstrated the greatest reductions, while the SGLT2 inhibitor group also showed improvements compared with other oral antidiabetic drugs. No significant differences were observed in HbA1c, body weight, lipid profile, renal function, or ASCVD risk score across groups. The findings suggest that SGLT2 inhibitor–based therapy is associated with meaningful blood pressure improvement, supporting cardiovascular benefits beyond glycemic control in real-world practice.
Read MoreA systematic review and meta-analysis compared GLP-1 receptor agonists and SGLT2 inhibitors in patients with type 2 diabetes and non-alcoholic fatty liver disease. Evidence from recent trials and meta-analyses demonstrated substantial cardiorenal, metabolic, and hepatic benefits with both drug classes. SGLT2 inhibitors were particularly effective in preventing heart failure, reducing cardiovascular mortality, and slowing renal progression. Subgroup analyses confirmed cardiovascular risk reduction regardless of baseline metformin use. While GLP-1 receptor agonists showed stronger effects on weight loss and glycemic control, SGLT2 inhibitors demonstrated greater effects on liver enzyme improvement. Overall, the findings support the broad cardiometabolic and hepatic benefits of SGLT2 inhibitors beyond glucose lowering.
Read MoreA pilot real-world study from a secondary hospital in Malaysia evaluated the impact of initiating sodium–glucose cotransporter 2 inhibitors in 76 patients with type 2 diabetes mellitus and chronic kidney disease. Following treatment initiation, serum creatinine showed a mild rise at three months but stabilized at six and twelve months. Over one year, estimated glomerular filtration rate declined modestly, remaining below ten percent. Importantly, blood glucose control improved, with mean HbA1c decreasing at three months and remaining stable thereafter. No meaningful association was observed between changes in HbA1c and kidney function during follow-up. Overall, the findings indicate that SGLT2 inhibitors were associated with stabilization of kidney function after the early treatment phase and sustained improvement in glycemic control in routine clinical practice.
Read MoreNew-generation antidiabetic agents, including sodium–glucose cotransporter 2 inhibitors (SGLT2i), offer benefits beyond glycemic control in patients undergoing cardiac surgery. A systematic review of studies published between 2020 and 2025 evaluated perioperative safety, cardiovascular outcomes, and renal function. SGLT2 inhibitors demonstrated significant cardioprotective and nephroprotective effects, including lower incidence of acute kidney injury, reduced inflammatory markers, and improved recovery after coronary artery bypass grafting. Importantly, these benefits were observed regardless of the presence of diabetes, highlighting a broader therapeutic potential. GLP-1 receptor agonists also improved perioperative glycemic control and cardiac recovery, whereas dipeptidyl peptidase-4 inhibitors showed inconsistent results. Overall, SGLT2 inhibitors emerged as safe and effective adjuncts in the perioperative setting, offering multi-organ protection and supporting their expanding role beyond blood glucose management.
Read MoreCombined therapy with sodium–glucose cotransporter 2 inhibitors (SGLT2i) and metformin (COMBI) demonstrates systemic metabolic benefits in type 2 diabetes beyond glycemic control. In a study of 1,494 participants, COMBI therapy significantly altered serum metabolite profiles, including urea cycle and ketone body markers, compared with metformin alone. Notably, levels of citrulline, asymmetric dimethyl arginine, and ornithine were elevated, correlating with reduced liver fibrosis risk. Additional modulation of threonine and glycine metabolism was observed, suggesting multi-organ protective effects. These findings highlight potential mechanisms through which SGLT2i-based combination therapy may protect against liver fibrosis and male subfertility, providing insight into its broader metabolic and systemic benefits in type 2 diabetes patients.
Read MoreA retrospective cohort study from Saudi Arabia evaluated dapagliflozin, an SGLT2 inhibitor, and semaglutide in 196 adults with type 2 diabetes managed in primary care. Over one year, dapagliflozin significantly improved glycemic control and reduced systolic blood pressure, reinforcing its cardiometabolic benefits beyond glucose lowering. Although no reduction in short-term cardiovascular events was observed, the improvements in blood pressure and metabolic parameters highlight its role in modifying atherosclerotic cardiovascular risk profiles. In high-prevalence diabetes populations, SGLT2 inhibitors may offer meaningful risk-factor optimization even before hard cardiovascular outcomes become evident. Longer-term studies are needed, but these findings support the expanding role of SGLT2 inhibitors as multi-system agents targeting more than hyperglycemia.
Read MoreA large real-world cohort study using the TriNetX database compared SGLT2 inhibitors with GLP-1 receptor agonists and DPP-4 inhibitors in over 190,000 adults with type 2 diabetes. SGLT2 inhibitor use was associated with significantly lower risks of open-angle glaucoma, ocular hypertension, cataract, diabetic retinopathy, and macular edema. These findings suggest a protective ocular effect beyond glycemic control, potentially mediated by hemodynamic, vascular, and anti-inflammatory mechanisms. While GLP-1 receptor agonists demonstrated stronger systemic protection in some domains, SGLT2 inhibitors stood out for reducing eye-related complications. For patients at high risk of diabetic ocular disease, SGLT2 inhibitors may offer an added organ-protective advantage as part of comprehensive diabetes management.
Read MoreA large systematic review and meta-analysis of 13 randomized controlled trials involving 84,581 participants evaluated the safety and renal impact of SGLT2 inhibitors across diverse populations, including individuals with and without type 2 diabetes. SGLT2 inhibitors were associated with a significant 20% reduction in acute kidney injury (RR 0.80; 95% CI 0.74–0.87), demonstrating a consistent renoprotective effect. Among patients with chronic kidney disease, renal composite outcomes were also significantly reduced (OR 0.70; 95% CI 0.62–0.79). While certain non-renal adverse events such as genital infections and hypovolemia were increased, hypoglycemia and amputation risks were not significantly different. These findings reinforce that SGLT2 inhibitors extend meaningful kidney protection beyond glycemic control, supporting their broader role in cardiorenal risk reduction.
Read MoreIn a large propensity-matched analysis of 3,074 patients with HER2-positive breast cancer and preserved ejection fraction, SGLT2 inhibitor use was associated with substantial survival benefits. Over 5 years, all-cause mortality was significantly lower in SGLT2 users (7.9% vs 19.6%; HR 0.53, p <0.001). Additionally, SGLT2 inhibitors reduced the risk of cerebral infarction, atrial fibrillation, sepsis, acute kidney injury, pneumonia, and diarrhea. Despite a higher incidence of heart failure events and ventricular tachycardia, the overall mortality and multi-system risk reduction signals were strongly favorable. These findings suggest that SGLT2 inhibitors may confer protective benefits extending beyond traditional cardiometabolic settings, highlighting their emerging role in complex oncology populations and reinforcing their impact beyond glycemic management.
Read MoreEmerging evidence suggests that SGLT2 inhibitors may offer benefits beyond cardiometabolic protection. In a large real-world emulated target trial using the TriNetX U.S. Collaborative Network (2015–2024), researchers compared 205,704 matched patients with type 2 diabetes initiating SGLT2 inhibitors versus DPP-4 inhibitors. Over follow-up, SGLT2 inhibitor use was associated with a significantly lower risk of incident multiple sclerosis (MS) (HR 0.78; 95% CI 0.63–0.97). The cumulative incidence of MS was also lower among SGLT2 users (0.067% vs 0.112%; log-rank p=0.025). The protective association was consistent across key subgroups, including women, individuals under 65 years, and those with well-controlled glycemia. Findings remained robust across sensitivity analyses. These results suggest a potential neuro-immunological benefit of SGLT2 inhibitors, reinforcing their expanding therapeutic impact beyond glycemic control.
Read MoreIn a prospective cohort of 614 patients with type 2 diabetes newly initiated on SGLT2 inhibitors, therapy was associated with significant improvement in subclinical left ventricular systolic function over 6 months. Global longitudinal strain (GLS) improved markedly in both normal-weight and overweight/obese groups (p<0.001 for both), with similar magnitude of benefit irrespective of BMI. While overweight patients experienced modest BMI reduction, baseline BMI was not predictive of cardiac improvement. Instead, baseline GLS strongly predicted functional gains. These findings suggest that SGLT2 inhibitors enhance myocardial performance independent of body weight changes. The study reinforces emerging evidence that SGLT2 inhibitors confer direct cardiovascular benefits beyond glucose lowering, extending their impact to early, subclinical cardiac dysfunction across the weight spectrum.
Read MoreA five-year retrospective cohort study from Thailand evaluated clinical outcomes in 1,378 patients with heart failure. Patients receiving SGLT2 inhibitors had significantly lower rates of the composite outcome of all-cause mortality or heart failure hospitalization compared with non-users (rate ratio 0.60; 95% CI 0.42–0.87; p=0.006). Notably, all-cause mortality was markedly reduced in the SGLT2 inhibitor group (rate ratio 0.02; p=0.001). These benefits were observed despite a higher burden of reduced ejection fraction, coronary artery disease, and chronic kidney disease among treated patients. The findings highlight the real-world cardiovascular effectiveness of SGLT2 inhibitors and support their broader implementation in heart failure management, reinforcing their role well beyond glycemic control.
Read MoreIn a large target trial emulation using the TriNetX database, 294,664 matched patients with type 2 diabetes initiating SGLT2 inhibitors were compared with GLP-1 receptor agonist users over a mean follow-up of 44 months. SGLT2 inhibitor use was associated with significantly lower incidence of renal cell carcinoma (HR 0.85; 95% CI 0.79–0.92) and urothelial cell carcinoma (HR 0.85; 95% CI 0.78–0.92). Results were consistent across demographic and comorbidity subgroups. These findings provide important comparative safety data and suggest a potential protective association against certain urologic malignancies. The study further expands the therapeutic narrative of SGLT2 inhibitors beyond glycemic management, into the domain of long-term oncologic risk modulation.
Read MoreIn a retrospective cohort of patients with diabetic kidney disease followed for 36 months, higher glycemic variability was strongly associated with faster eGFR decline and increased risk of renal events. Notably, subgroup analyses showed that adverse outcomes were more pronounced in patients not treated with SGLT2 inhibitors, suggesting a potential protective renal effect. While the primary focus was glycemic variability, the data indirectly reinforce the renoprotective role of SGLT2 inhibitors in slowing diabetic kidney disease progression. These findings align with growing evidence that SGLT2 inhibitors extend benefits beyond glucose control, particularly in preserving renal function and mitigating long-term complications in high-risk patients.
Read MoreA single-center retrospective study compared oral semaglutide and SGLT2 inhibitors in patients with type 2 diabetes who continued therapy for at least six months. Among 231 patients receiving SGLT2 inhibitors, significant reductions were observed in HbA1c (−0.86%), body weight (−2.30 kg), and fat mass (−1.93 kg) at six months. These improvements were comparable to those seen with oral semaglutide. The findings confirm that SGLT2 inhibitors provide meaningful glycemic and weight benefits in routine clinical practice. Although a reduction in skeletal muscle mass was noted in the SGLT2 inhibitor group, overall metabolic outcomes demonstrated effective glucose lowering and body composition improvement. The study supports the clinical utility of SGLT2 inhibitors for comprehensive metabolic management in type 2 diabetes.
Read More